Top

Breast Cancer Research and Treatment

Published in:

01-08-2011 | Letter to the Editor

XPC gene polymorphisms and breast cancer susceptibility: appraisal of a recent meta-analysis

Authors: Fang Wang, Yan-Feng Zou, Guo-Ping Sun

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Excerpt

To the Editor, …

Zheng W, Cong XF, Cai WH, Yang S, Mao C, Zou HW (2011) Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. doi 10.1007/s10549-011-1369-6

Khan SG, Muniz-Medina V, Shahlavi T, Baker CC, Inui H, Ueda T, Emmert S, Schneider TD, Kraemer KH (2002) The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res 30:3624–3631PubMedCrossRef

Blankenburg S, König IR, Moessner R, Laspe P, Thoms KM, Krueger U, Khan SG, Westphal G, Berking C, Volkenandt M, Reich K, Neumann C, Ziegler A, Kraemer KH, Emmert S (2005) Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis 26:1085–1090PubMedCrossRef

Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE (2005) The polyAT, intronic IVS11–6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. Br J Cancer 92:2262–2265PubMedCrossRef

Shore RE, Zeleniuch-Jacquotte A, Currie D, Mohrenweiser H, Afanasyeva Y, Koenig KL, Arslan AA, Toniolo P, Wirgin I (2008) Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk. Int J Cancer 122:2101–2105PubMedCrossRef

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCrossRef

Hunter CP (2000) Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 88:1193–1202PubMedCrossRef

Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The International HapMap Project web site. Genome Res 15:1592–1593PubMedCrossRef

Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef

Title: XPC gene polymorphisms and breast cancer susceptibility: appraisal of a recent meta-analysis
Authors: Fang Wang
Yan-Feng Zou
Guo-Ping Sun
Publication date: 01-08-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1493-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Effects of estrogen on the proportion of stem cells in the breast

Erratum to: Postmenopausal estrogen monotherapy–associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism

The benefits of discussing adjuvant therapies one at a time instead of all at once

Characterizing the impact of 25 years of DCIS treatment

Alcohol, tobacco, and mammographic density: a population-based study

MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements

Keynote webinar | Spotlight on antibody–drug conjugates in cancer